Resistance to chemotherapy in ovarian carcinoma.
Resistance to cytotoxic chemotherapy is the main cause of therapeutic failure and death in women suffering from ovarian carcinoma. The standard first-line chemotherapy of ovarian cancer consists of a combination of a taxane and a platinum-containing drug. Thus, the cellular and molecular mechanisms involved in resistance against these compounds are of vital importance in the context of chemotherapy of ovarian cancer. This review will discuss the current state of knowledge of drug resistance-associated factors and their impact on clinical chemotherapy response in ovarian carcinoma as well as different strategies for reversal of drug resistance.
Lage
Hermann
H
Institute of Pathology, Charité Campus Mitte, Berlin, Germany.
Denkert
Carsten
C
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002277:Carcinoma / Q000188:drug therapy* / Q000378:metabolism; D019008:Drug Resistance, Neoplasm; D005260:Female; D006801:Humans; D009944:Organoplatinum Compounds / Q000627:therapeutic use*; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000378:metabolism; D043823:Taxoids / Q000627:therapeutic use*
D000970:Antineoplastic Agents; D009944:Organoplatinum Compounds; D043823:Taxoids